ArticlePloS one2015
Unexpected Regulatory Role of CCR9 in Regulatory T Cell Development.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Frontiers in immunology · 2022Pooled it
- Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence.Current opinion in allergy and clinical immunology · 2018Pooled it
- Changes in peripheral immune populations during pregnancy and modulation by probiotics and ω-3 fatty acids.Scientific reports · 2020Trial
- Extremely Preterm Infants Have Significant Alterations in Their Conventional T Cell Compartment during the First Weeks of Life.Journal of immunology (Baltimore, Md. : 1950) · 2020Trial
- Decoding Treg diversity and dysfunction to advance Treg-based therapies in autoimmune and inflammatory diseases.Frontiers in immunology · 2026Review
- Reversing Dysfunction of CCR9Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Gut microbiota in asthma: mechanisms, clinical evidence, and therapeutic opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.Cancer science · 2024Article
- Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy.Nanomedicine (London, England) · 2024Review
- Canine peripheral blood TCRαβ T cell atlas: Identification of diverse subsets including CD8AFrontiers in immunology · 2023Article
- Setd2 supports GATA3Nature communications · 2022Article
- Chemokine-Driven Migration of Pro-Inflammatory CD4Frontiers in immunology · 2022Review
- The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases.Frontiers in cell and developmental biology · 2021Review
- Propionate supplementation promotes the expansion of peripheral regulatory T-Cells in patients with end-stage renal disease.Journal of nephrology · 2020Article
- Dysregulated Mucosal Immunity and Associated Pathogeneses in Preterm Neonates.Frontiers in immunology · 2020Review
- Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9Science advances · 2020Article
- The role of chemokine receptor 9/chemokine ligand 25 signaling: From immune cells to cancer cells.Oncology letters · 2018Review
- Macrophage Subset Expressing CD169 in Peritoneal Cavity-Regulated Mucosal Inflammation Together with Lower Levels of CCL22.Inflammation · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
T cells reactive to microbiota regulate the pathogenesis of inflammatory bowel disease (IBD). As T cell trafficking to intestines is regulated through interactions between highly specific chemokine-chemokine receptors, efforts have been made to develop intestine-specific immunosuppression based on blocking these key processes. CCR9, a gut-trophic chemokine receptor expressed by lymphocytes and dendritic cells, has been implicated in the regulation of IBD through mediating recruitment of T cells to inflamed sites. However, the role of CCR9 in inducing and sustaining inflammation in the context of IBD is poorly understood. In this study, we demonstrate that CCR9 deficiency in effector T cells and Tregs does not affect the development of colitis in a microbiota antigen-specific, T cell-mediated model. However, Treg cells express higher levels of CCR9 compared to those in effector T cells. Interestingly, CCR9 inhibits Treg cell development, in that CCR9-/- mice demonstrate a high level of Foxp3+ Tregs, and ligation of CCR9 by its ligand CCL25 inhibits Treg cell differentiation in vitro. Collectively, our data indicate that in addition to acting as a gut-homing molecule, CCR9 signaling shapes immune responses by inhibiting Treg cell development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.